Flagellin produced in plants is a potent adjuvant for oral immunization

Vaccine

Volumn 29, Issue 38, 2011, Pages 6695-6703

  Girard, Aurélie ^a   Saron, Wilfried ^a   Bergeron Sandoval, Louis Philippe ^a   Sarhan, Fathey ^a   Archambault, Denis ^a  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

Adjuvant; Flagellin; Oral immunization; Transgenic plant

Indexed keywords

FLAGELLIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G2B; OVALBUMIN; OVALBUMIN PLUS FLAGELLIN FLJB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MANUFACTURE; DRUG POTENCY; DRUG RESPONSE; FEMALE; IMMUNIZATION; MOUSE; NICOTIANA BENTHAMIANA; NONHUMAN; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; SPLEEN LYMPHOCYTE; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES; FEMALE; FLAGELLIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; OVALBUMIN; PLANTS, GENETICALLY MODIFIED; RECOMBINANT PROTEINS; SALMONELLA TYPHIMURIUM; TECHNOLOGY, PHARMACEUTICAL; TOBACCO; VACCINES, SUBUNIT;

EID: 80051667914     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.06.092     Document Type: Article

References (68)

1. Plotkin S.A. Vaccines: past, present and future. Nat Med 2005, 11(Suppl. 4):S5-S11.
2. Wang J., Thorson L., Stokes R.W., Santosuosso M., Huygen K., Zganiacz A., et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 2004, 173(10):6357-6365.
3. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6(2):148-158.
4. Kozlowski P.A., Cu-Uvin S., Neutra M.R., Flanigan T.P. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun 1997, 65(4):1387-1394.
5. Belyakov I.M., Hel Z., Kelsall B., Kuznetsov V.A., Ahlers J.D., Nacsa J., et al. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med 2001, 7(12):1320-1326.
6. Belyakov I.M., Ahlers J.D. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens?. J Immunol 2009, 183(11):6883-6892.
7. Silin D.S., Lyubomska O.V., Jirathitikal V., Bourinbaiar A.S. Oral vaccination: where we are?. Expert Opin Drug Deliv 2007, 4(4):323-340.
8. Mason K.L., Huffnagle G.B., Noverr M.C., Kao J.Y. Overview of gut immunology. Adv Exp Med Biol 2008, 635:1-14.
9. Plotkin S.A. Vaccines: the fourth century. Clin Vaccine Immunol 2009, 16(12):1709-1719.
10. Lugade A.A., Kalathil S., Heald J.L., Thanavala Y. Transgenic plant-based oral vaccines. Immunol Invest 2010, 39(4-5):468-482.
11. Simon J., Kotloff K. New and candidate vaccines for gastrointestinal infections. Curr Opin Gastroenterol 2010, 26(1):12-16.
12. Mowat A.M., Parker L.A., Beacock-Sharp H., Millington O.R., Chirdo F. Oral tolerance: overview and historical perspectives. Ann N Y Acad Sci 2004, 1029:1-8.
13. Mowat A.M. Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol 2003, 3(4):331-341.
14. Soares-Weiser K., Maclehose H., Ben-Aharon I., Goldberg E., Pitan F., Cunliffe N. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev 2010, 5:CD008521.
15. Ehrenfeld E., Modlin J., Chumakov K. Future of polio vaccines. Expert Rev Vaccines 2009, 8(7):899-905.
16. Bishop R. Discovery of rotavirus: implications for child health. J Gastroenterol Hepatol 2009, 24(Suppl. 3):S81-S85.
17. Davoodi-Semiromi A., Samson N., Daniell H. The green vaccine: a global strategy to combat infectious and autoimmune diseases. Hum Vaccine 2009, 5(7):488-493.
18. Vezina L.P., Faye L., Lerouge P., D'Aoust M.A., Marquet-Blouin E., Burel C., et al. Transient co-expression for fast and high-yield production of antibodies with human-like N-glycans in plants. Plant Biotechnol J 2009, 7(5):442-455.
19. Daniell H., Singh N.D., Mason H., Streatfield S.J. Plant-made vaccine antigens and biopharmaceuticals. Trends Plant Sci 2009, 14(12):669-679.
20. Granell A., Fernandez del-Carmen A., Orazez D. In planta production of plant-derived and non-plant-derived adjuvants. Expert Rev Vaccines 2010, 9(8):843-858.
21. Landry N., Ward B.J., Trepanier S., Montomoli E., Dargis M., Lapini G., et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 2010, 5(12):e15559.
22. Sala F., Manuela Rigano M., Barbante A., Basso B., Walmsley A.M., Castiglione S. Vaccine antigen production in transgenic plants: strategies, gene constructs and perspectives. Vaccine 2003, 21(7-8):803-808.
23. Mishra N., Goyal A.K., Tiwari S., Paliwal R., Paliwal S.R., Vaidya B., et al. Recent advances in mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymeric carriers. Expert Opin Ther Pat 2010, 20(5):661-679.
24. Reed S.G., Bertholet S., Coler R.N., Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009, 30(1):23-32.
25. Sun H.X., Xie Y., Ye Y.P. ISCOMs and ISCOMATRIX. Vaccine 2009, 27(33):4388-4401.
26. Gosselin E.J., Bitsaktsis C., Li Y., Iglesias B.V. Fc receptor-targeted mucosal vaccination as a novel strategy for the generation of enhanced immunity against mucosal and non-mucosal pathogens. Arch Immunol Ther Exp (Warsz) 2009, 57(5):311-323.
27. Summerton N.A., Welch R.W., Bondoc L., Yang H.H., Pleune B., Ramachandran N., et al. Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. Vaccine 2010, 28(5):1404-1411.
28. Lavelle E.C., Grant G., Pusztai A., Pfuller U., O'Hagan D.T. The identification of plant lectins with mucosal adjuvant activity. Immunology 2001, 102(1):77-86.
29. Cooper C.L., Angel J.B., Seguin I., Davis H.L., Cameron D.W. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis 2008, 46(8):1310-1314.
30. Murad Y.M., Clay T.M. CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer. BioDrugs 2009, 23(6):361-375.
31. Yonekura K., Maki-Yonekura S., Namba K. Building the atomic model for the bacterial flagellar filament by electron cryomicroscopy and image analysis. Structure 2005, 13(3):407-412.
32. Miao E.A., Andersen-Nissen E., Warren S.E., Aderem A. TLR5 and Ipaf: dual sensors of bacterial flagellin in the innate immune system. Semin Immunopathol 2007, 29(3):275-288.
33. Gewirtz A.T., Navas T.A., Lyons S., Godowski P.J., Madara J.L. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol 2001, 167(4):1882-1885.
34. Rhee S.H., Keates A.C., Moyer M.P., Pothoulakis C. MEK is a key modulator for TLR5- induced interleukin-8 and MIP3alpha gene expression in non-transformed human colonic epithelial cells. J Biol Chem 2004, 279(24):25179-25188.
35. Pino O., Martin M., Michalek S.M. Cellular mechanisms of the adjuvant activity of the flagellin component FljB of Salmonella enterica Serovar Typhimurium to potentiate mucosal and systemic responses. Infect Immun 2005, 73(10):6763-6770.
36. Means T.K., Hayashi F., Smith K.D., Aderem A., Luster A.D. The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. J Immunol 2003, 170(10):5165-5175.
37. Sierro F., Dubois B., Coste A., Kaiserlian D., Kraehenbuhl J.P., Sirard J.C. Flagellin stimulation of intestinal epithelial cells triggers CCL20-mediated migration of dendritic cells. Proc Natl Acad Sci U S A 2001, 98(24):13722-13727.
38. Rhee S.H., Kim H., Moyer M.P., Pothoulakis C. Role of MyD88 in phosphatidylinositol 3-kinase activation by flagellin/toll-like receptor 5 engagement in colonic epithelial cells. J Biol Chem 2006, 281(27):18560-18568.
39. Salman H.H., Irache J.M., Gamazo C. Immunoadjuvant capacity of flagellin and mannosamine-coated poly(anhydride) nanoparticles in oral vaccination. Vaccine 2009, 27(35):4784-4790.
40. Takata T., Shirakawa T., Kawasaki Y., Kinoshita S., Gotoh A., Kano Y., et al. Genetically engineered Bifidobacterium animalis expressing the Salmonella flagellin gene for the mucosal immunization in a mouse model. J Gene Med 2006, 8(11):1341-1346.
41. Bargieri D.Y., Leite J.A., Lopes S.C., Sbrogio-Almeida M.E., Braga C.J., Ferreira L.C., et al. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium. Vaccine 2010, 28(16):2818-2826.
42. Honko A.N., Sriranganathan N., Lees C.J., Mizel S.B. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect Immun 2006, 74(2):1113-1120.
43. Lee S.E., Kim S.Y., Jeong B.C., Kim Y.R., Bae S.J., Ahn O.S., et al. A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect Immun 2006, 74(1):694-702.
44. Skountzou I., Martin Mdel P., Wang B., Ye L., Koutsonanos D., Weldon W., et al. Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine 2010, 28(24):4103-4112.
45. Song L., Zhang Y., Yun N.E., Poussard A.L., Smith J.N., Smith J.K., et al. Superior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin. Vaccine 2009, 27(42):5875-5884.
46. Huleatt J.W., Nakaar V., Desai P., Huang Y., Hewitt D., Jacobs A., et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26(2):201-214.
47. Bergeron-Sandoval L.P., Girard A., Ouellet F., Archambault D., Sarhan F. Production of human rotavirus and Salmonella antigens in plants and elicitation of fljB-specific humoral responses in mice. Mol Biotechnol 2011, 47(2):157-168.
48. Kane N.A., Agharbaoui Z., Diallo A.O., Adam H., Tominaga Y., Ouellet F., et al. TaVRT2 represses transcription of the wheat vernalization gene TaVRN1. Plant J 2007, 51(4):670-680.
49. McDermott P.F., Ciacci-Woolwine F., Snipes J.A., Mizel S.B. High-affinity interaction between gram-negative flagellin and a cell surface polypeptide results in human monocyte activation. Infect Immun 2000, 68(10):5525-5529.
50. Rigano M.M., Dreitz S., Kipnis A.P., Izzo A.A., Walmsley A.M. Oral immunogenicity of a plant-made, subunit, tuberculosis vaccine. Vaccine 2006, 24(5):691-695.
51. Abdul-Wahid A., Faubert G. Mucosal delivery of a transmission-blocking DNA vaccine encoding Giardia lamblia CWP2 by Salmonella typhimurium bactofection vehicle. Vaccine 2007, 25(50):8372-8383.
52. Oliveira F.M., Silva-Neto A.F., Silva C.A., Gontijo C.M. Coupling of palmitate to ovalbumin inhibits the induction of oral tolerance. Braz J Med Biol Res 1998, 31(11):1421-1424.
53. Huleatt J.W., Jacobs A.R., Tang J., Desai P., Kopp E.B., Huang Y., et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 2007, 25(4):763-775.
54. Sun J.B., Czerkinsky C., Holmgren J. Mucosally induced immunological tolerance, regulatory T cells and the adjuvant effect by cholera toxin B subunit. Scand J Immunol 2010, 71(1):1-11.
55. Tincer G., Yerlikaya S., Yagci F.C., Kahraman T., Atanur O.M., Erbatur O., et al. Immunostimulatory activity of polysaccharide-poly(I:C) nanoparticles. Biomaterials 2011, 32(18):4275-4282.
56. Plebanski M., Katsara M., Sheng K.C., Xiang S.D., Apostolopoulos V. Methods to measure T-cell responses. Expert Rev Vaccines 2010, 9(6):595-600.
57. Kajal H., Misra A. Preparation of tetanus toxoid and ovalbumin loaded gliadin nanoparticles for oral immunization. J Biomed Nanotechnol 2011, 7(1):211-212.
58. Li J., Guo J., Su Z., Hu M., Liu W., Wei Q. Calcineurin subunit B activates dendritic cells and acts as a cancer vaccine adjuvant. Int Immunol 2011, 23(5):327-334.
59. Sarti F., Perera G., Hintzen F., Kotti K., Karageorgiou V., Kammona O., et al. In vivo evidence of oral vaccination with PLGA nanoparticles containing the immunostimulant monophosphoryl lipid A. Biomaterials 2011, 32(16):4052-4057.
60. Varshney G.C., Mahana W., Filloux A.M., Venien A., Paraf A.V. Structure of native and heat- denaturated ovalbumin as revealed by monoclonal antibodies epitopic changes during heat treatment. J Food Sci 1991, 56(1):224-227.
61. Arlen P.A., Singleton M., Adamovicz J.J., Ding Y., Davoodi-Semiromi A., Daniell H. Effective plague vaccination via oral delivery of plant cells expressing F1-V antigens in chloroplasts. Infect Immun 2008, 76(8):3640-3650.
62. Limaye A., Koya V., Samsam M., Daniell H. Receptor-mediated oral delivery of a bioencapsulated green fluorescent protein expressed is transgenic chloroplasts into the mouse circulatory system. FASEB J 2006, 20(7):959-961.
63. Vicente-Suarez I., Brayer J., Villagra A., Cheng F., Sotomayor E.M. TLR5 ligation by flagellin converts tolerogenic dendritic cells into activating antigen-presenting cells that preferentially induce T-helper 1 responses. Immunol Lett 2009, 125(2):114-118.
64. Cuadros C., Lopez-Hernandez F.J., Dominguez A.L., McClelland M., Lustgarten J. Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses. Infect Immun 2004, 72(5):2810-2816.
65. Didierlaurent A., Ferrero I., Otten L.A., Dubois B., Reinhardt M., Carlsen H., et al. Flagellin promotes myeloid differentiation factor 88-dependent development of Th2- type response. J Immunol 2004, 172(11):6922-6930.
66. Alaniz R.C., Cummings L.A., Bergman M.A., Rassoulian-Barrett S.L., Cookson B.T. Salmonella typhimurium coordinately regulates FliC location and reduces dendritic cell activation and antigen presentation to CD4+ T cells. J Immunol 2006, 177(6):3983-3993.
67. Merrell D.S., Falkow S. Frontal and stealth attack strategies in microbial pathogenesis. Nature 2004, 430(6996):250-256.
68. Ben-Yedidia T., Arnon R. Effect of pre-existing carrier immunity on the efficacy of synthetic influenza vaccine. Immunol Lett 1998, 64(1):9-15.